Life Biosciences Secures $80 Million Series D Financing

Funding to support Phase 1 trial of ER-100 for optic neuropathies and advance Partial Epigenetic Reprogramming platform

Apr. 8, 2026 at 2:11pm

Got story updates? Submit your updates here. ›

Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies, has announced the close of an $80 million Series D financing. The proceeds will support the company's operations, including the completion of its recently initiated Phase 1 clinical trial of ER-100 for optic neuropathies and the continued advancement of its Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications.

Why it matters

Life Biosciences' PER platform offers the potential to address a wide range of age-related diseases by targeting a root cause of aging at the epigenetic level. The successful Series D financing reflects growing interest in the company's innovative approach and its ability to deliver disease-modifying solutions for patients.

The details

The $80 million financing will enable Life Biosciences to advance its lead program, ER-100, through key clinical milestones and continue the expansion of its broader pipeline. ER-100 is currently in a Phase 1 clinical trial to assess its safety and tolerability in patients with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), two optic neuropathies characterized by damage to retinal ganglion cells that cannot naturally regenerate, leading to permanent vision impairment.

  • Life Biosciences initiated the Phase 1 clinical trial of ER-100 in the first quarter of 2026.
  • The $80 million Series D financing was closed in April 2026.

The players

Life Biosciences, Inc.

A clinical-stage biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging.

Jerry McLaughlin

Chief Executive Officer of Life Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging.”

— Jerry McLaughlin, Chief Executive Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Life Biosciences' successful Series D financing highlights the potential of its Partial Epigenetic Reprogramming platform to address a wide range of age-related diseases, including optic neuropathies, by targeting the root causes of aging at the cellular level.